Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Dhingra

Showing results (241-250 of 264) with videos related to

Pageof 27
Sort By:
Scientific Reports|September 13, 2018
Evidence for Regulation of Hemoglobin Metabolism and Intracellular Ionic Flux by the Plasmodium falciparum Chloroquine Resistance TransporterAndrew H Lee, Satish K Dhingra, Ian A Lewis, et al.
JACC. Heart Failure|September 16, 2023
Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF: Post-Hoc Analysis of EMPEROR-ReducedNitish K Dhingra, Subodh Verma, Javed Butler, et al.
CJC Open|January 16, 2026
Expert Perspectives on a Randomized Controlled Trial Comparing Novel Donor Storage Platforms to Cold-static Preservation for Heart TransplantationReem Alsaeid, Nitish K Dhingra, James Stevenson, et al.
Mbio|December 7, 2023
Additional PfCRT mutations driven by selective pressure for improved fitness can result in the loss of piperaquine resistance and altered <i>Plasmodium falciparum</i> physiologyLaura M Hagenah, Satish K Dhingra, Jennifer L Small-Saunders, et al.
The Annals of Thoracic Surgery|July 2, 2022
Risk Factors for Postrepair Elevated Mitral Gradient: A Post-hoc Analysis of a Randomized TrialMakoto Hibino, Arjun K Pandey, Vincent Chan, et al.
Plos Pathogens|November 11, 2016
Evolution of Fitness Cost-Neutral Mutant PfCRT Conferring P. falciparum 4-Aminoquinoline Drug Resistance Is Accompanied by Altered Parasite Metabolism and Digestive Vacuole PhysiologyStanislaw J Gabryszewski, Satish K Dhingra, Jill M Combrinck, et al.
Molecular Microbiology|April 23, 2015
Balancing drug resistance and growth rates via compensatory mutations in the Plasmodium falciparum chloroquine resistance transporterInes Petersen, Stanislaw J Gabryszewski, Geoffrey L Johnston, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapyH M Kuerer, L A Newman, T L Smith, et al.
Nature|November 29, 2019
Structure and drug resistance of the Plasmodium falciparum transporter PfCRTJonathan Kim, Yong Zi Tan, Kathryn J Wicht, et al.
The Journal of Infectious Diseases|December 8, 2022
Integrative Genetic Manipulation of Plasmodium cynomolgi Reveals Multidrug Resistance-1 Y976F Associated With Increased In Vitro Susceptibility to MefloquineKurt E Ward, Peter Christensen, Annie Racklyeft, et al.
Pageof 27

Showing results (241-250 of 264) with videos related to

Sort By:
Pageof 27
Scientific Reports|September 13, 2018
Evidence for Regulation of Hemoglobin Metabolism and Intracellular Ionic Flux by the Plasmodium falciparum Chloroquine Resistance TransporterAndrew H Lee, Satish K Dhingra, Ian A Lewis, et al.
JACC. Heart Failure|September 16, 2023
Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF: Post-Hoc Analysis of EMPEROR-ReducedNitish K Dhingra, Subodh Verma, Javed Butler, et al.
CJC Open|January 16, 2026
Expert Perspectives on a Randomized Controlled Trial Comparing Novel Donor Storage Platforms to Cold-static Preservation for Heart TransplantationReem Alsaeid, Nitish K Dhingra, James Stevenson, et al.
Mbio|December 7, 2023
Additional PfCRT mutations driven by selective pressure for improved fitness can result in the loss of piperaquine resistance and altered <i>Plasmodium falciparum</i> physiologyLaura M Hagenah, Satish K Dhingra, Jennifer L Small-Saunders, et al.
The Annals of Thoracic Surgery|July 2, 2022
Risk Factors for Postrepair Elevated Mitral Gradient: A Post-hoc Analysis of a Randomized TrialMakoto Hibino, Arjun K Pandey, Vincent Chan, et al.
Plos Pathogens|November 11, 2016
Evolution of Fitness Cost-Neutral Mutant PfCRT Conferring P. falciparum 4-Aminoquinoline Drug Resistance Is Accompanied by Altered Parasite Metabolism and Digestive Vacuole PhysiologyStanislaw J Gabryszewski, Satish K Dhingra, Jill M Combrinck, et al.
Molecular Microbiology|April 23, 2015
Balancing drug resistance and growth rates via compensatory mutations in the Plasmodium falciparum chloroquine resistance transporterInes Petersen, Stanislaw J Gabryszewski, Geoffrey L Johnston, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapyH M Kuerer, L A Newman, T L Smith, et al.
Nature|November 29, 2019
Structure and drug resistance of the Plasmodium falciparum transporter PfCRTJonathan Kim, Yong Zi Tan, Kathryn J Wicht, et al.
The Journal of Infectious Diseases|December 8, 2022
Integrative Genetic Manipulation of Plasmodium cynomolgi Reveals Multidrug Resistance-1 Y976F Associated With Increased In Vitro Susceptibility to MefloquineKurt E Ward, Peter Christensen, Annie Racklyeft, et al.
Pageof 27